A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Active, not recruiting · Phase 3 · NCT03519945
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $279,669
- U.S. investigators named
- 24
- Sites paid
- 18
- Planned or actual enrollment
- 1,058
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Mirikizumab (drug)
- Dates
- Started 2018-07-18; completion 2027-12
- Results posted
- Not yet
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
From ClinicalTrials.gov, last updated 2026-04-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $279,669 in research payments for this study in 2025 (29 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Paul B. Lamb, MD Gastroenterology · Dothan, AL
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Connie Hsu, MD Allergy & Immunology · Litchfield Park, AZ
- Indu Srinivasan, M.D. Gastroenterology · Phoenix, AZ
- Mark H. Kogan, M.D. Gastroenterology · San Pablo, CA
- Ilan Aharoni, M.D. Gastroenterology · Tavares, FL
- Lucky Flores, M.D. Family Medicine · Miami Lakes, FL
- Ioannis Economou, M.D. Gastroenterology · Glenview, IL
- Monika Fischer, MD Gastroenterology · Indianapolis, IN
- Nicholas J. Kamp, M.D. Cardiology · Indianapolis, IN
- Michael Barker JR., MD Gastroenterology · Baton Rouge, LA
- Henry H. Hinkle III, M.D. Gastroenterology · Monroe, LA
- Ronald Fogel, MD Gastroenterology · Chesterfield, MI
- Daniel M. Van Handel, M.D. Gastroenterology · Plymouth, MN
- Animesh Jain, M.D. Student in an Organized Health Care Education/Training Program · New York, NY
- Le-chu Su, MD Gastroenterology · New York, NY
- Sayed M. Yossef, M.D. Gastroenterology · Poland, OH
- Ijlal Akbar Ali, MD Gastroenterology · Oklahoma City, OK
- Glenn S. Freed, DO Gastroenterology · Pottsville, PA
- Robert A. Gordon, MD Hematology & Oncology · Camp Hill, PA
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
- Jeff Bullock, M.D. Gastroenterology · San Antonio, TX
- Timothy E. Ritter, M.D. Gastroenterology · Southlake, TX
- Chad M. Gonzales, M.D. Gastroenterology · Ogden, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Digestive Disease Consultants $72,650
- Care Access Research LLC $69,648
- Noahs Ark Pediatrics $52,783
- Northshore University Healthsystem - Evanston Hospital, IL $19,274
- Central Sooner Research Inc $17,547
- Henry Ford Macomb Health Center $9,500
- Indiana University $7,108
- Board of Regents of the University of Oklahoma Health Sciences Center - Ouhsc, College of Medicine, $5,750
- $5,570
- University of North Carolina at Chapel Hill $4,949
- Trustees of Columbia Univ in The City of Ny $3,064
- Adventhealth Orlando, FL $3,000
- Wellness Clinical Research LLC $3,000
- Southern Star Research Institute LLC $2,000
- Minnesota Gastroenterology PA $1,820
- Valleywise Health Medical Center, AZ $750
- Delta Research PArtners LLC $713
- Cleveland Clinic, OH $472
- Digestive Health Specialists $70
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.